CHRS

Coherus Oncology, Inc. develops and commercializes next-generation immuno-oncology therapies aimed at improving cancer treatment and extending patient survival. The company’s portfolio includes LOQTORZI® (toripalimab-tpzi), an FDA-approved anti-PD-1 monoclonal antibody for treating recurrent, locally advanced, or metastatic nasopharyngeal carcinoma. Coherus is engaged in multiple clinical trials to assess the safety and effectiveness of its investigational drug candidates targeting the tumor microenvironment across various cancer indications.